Merck (NYSE: MRK) entered into a non-exclusive agreement with Bristol-Myers Squibb (NYSE: BMY) to conduct a Phase II clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE